Search

Caroxazone

Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. … However, it presents a five-fold preference for the MAO-B subtype.

ACY001

Otamixaban

Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

PB127

Cediranib

The novel indole-ether quinazoline Cediranib is a highly potent (IC₅₀ < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Cat dander extract

It is used in the diagnosis and treatment (immunotherapy) of patients with a history of allergy to cats. … Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.

Rolofylline

Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

Dexloxiglumide

Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

VTP-201227

It is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

Flurazepam

A benzodiazepine derivative used mainly as a hypnotic.